


## HDAC6-IN-29

<b>Cat. No.:</b>	HY-157401
<b>Molecular Formula:</b>	C <sub>38</sub> H <sub>51</sub> ClFN <sub>5</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	680.29
<b>Target:</b>	HDAC; Apoptosis
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	HDAC6-IN-29 (compound 11g), hydroxamic analogue, is a HDAC6 inhibitor. HDAC6-IN-29 has potent antiproliferative activity against CAL-51 cells (IC <sub>50</sub> = 1.17 μM) and is able to induce apoptosis and cause accumulation of cells in the S phase of the cell cycle. HDAC6-IN-29 can be used for the research of cancer <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 1.17 μM (CAL-51 cells) <sup>[1]</sup> .

### REFERENCES

[1]. Dai L, et al. Exploring Derivatives of Quinolizidine Alkaloid Sophoridine in the Design and Biological Mechanistic Evaluation of Histone Deacetylase Inhibitors for Triple-Negative Breast Cancer [J]. ChemMedChem, 2023: e202300467.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA